Previous close | 0.1682 |
Open | 0.1700 |
Bid | 0.1600 x 40700 |
Ask | 0.1699 x 1000 |
Day's range | 0.1622 - 0.1752 |
52-week range | 0.1300 - 1.2300 |
Volume | |
Avg. volume | 1,454,269 |
Market cap | 19.478M |
Beta (5Y monthly) | 0.42 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.3470 |
Earnings date | 26 July 2022 - 01 Aug 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 5.00 |
Patients demonstrated statistically significant improvements in several hormonal and cardiometabolic parameters following treatment with DCCRREDWOOD CITY, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today presented new positive clinical data from its ongoing late-stage DCCR development program for the treatment of Prader-Will
REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced presentations at the upcoming ENDO 2022, which is being held June 11-14, 2022, in Atlanta, Georgia, USA. Details of the presentations are as follows: 2022 Endocrine Society Meeting (ENDO) Title:Hormonal and Cardiometabolic Changes Associated with Diazoxide Choline E
REDWOOD CITY, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced presentations at the upcoming 2022 European Congress of Endocrinology (ECE), which is being held May 21-24, 2022, in Milan, Italy. Details of the presentations are as follows: 2022 European Congress of Endocrinology (ECE) Title:DCCR UpdateFormat:Presentation at the I